CG MEDTECH, DIAGNOSTICS AND DIGITAL HEALTH & SERVICES FORUM - MIMEDX GROUP INC

Explicit Guidance:

• No specific numerical guidance provided for future revenue, earnings, margins, or cash flow in this transcript.
• FY2027 outlook implied via the "pending near-term acquisition of Sonara" targeting a combined top line of ~$400 million.
• No specific guidance on share count, dividends, buybacks, or tax rates provided beyond the announcement of a completed share repurchase earlier in the year.

Business-Segment Outlook:

• Surgical Franchise: Expected to become the primary revenue engine, projected to represent approximately 75% (three-quarters) of the combined company's revenue post-Sonara acquisition.
• Surgical Volume: Anticipates continued double-digit volume growth for the surgical franchise.
• Wound Care Franchise: Expects recovery to be "non-linear" and "sluggish" due to 2026 Medicare reimbursement reforms, though the company views Q3 2026 as an inflection point with improving margins and EBITDA.
• Revenue Mix: Management intends to shift the portfolio mix toward surgical products, which are characterized as more durable and growing faster than the wound franchise.
• Product Pipeline: Two 510(k) submissions for surgical innovations are currently with the FDA, with a target to bring these to market in the "near term."
• Specific Product Data: EpiEffect randomized controlled trial (RCT) results are expected to be published "later this year" (2026).

Market and Competitive Outlook:

• Addressable Market: The Sonara acquisition is expected to unlock over $4 billion in incremental addressable markets, specifically targeting no-rinse irrigation and bone fixation segments.
• Payer Coverage: 2027 Medicare Physician Fee Schedule (PFS) and Outpatient Prospective Payment System (OPPS) confirm that 2026 reform measures remain "status quo," providing structural certainty for next year's reimbursement rates.
• Competitive Positioning: Aims to become the "largest truly dedicated regenerative medicine company" in the space, leveraging a "broad IP portfolio," "vertically integrated supply chain," and "leading payer coverage."
• Share Shift: Management asserts they are "taking share" in the wound care space despite the challenging reimbursement environment, driven by the most studied human placental allografts.

Macro / Industry Outlook:

• Medicare Reforms: The 2026 reimbursement overhaul is identified as the primary headwind impacting the wound franchise, having "drastically reduced spending" and made recovery "non-linear."
• Market Dynamics: Chronic wounds remain a "large and growing problem" for the aging population, providing a structural tailwind for efficacy-based product usage.
• Regulatory Timing: The acquisition of Sonara is contingent on FTC approval; the company is currently responding to a "second request" and aims to complete the deal "as quickly as possible."

Strategic Initiatives:

• Acquisition (Sonara MedTech): Pending acquisition expected to result in a ~$400 million top-line, surgical-led company with >20% adjusted EBITDA margins in the first year of combination.
• Strategic Shift: Reorganized infrastructure in 2026 to align with market shifts, specifically focusing on "shifting mix towards surgical" and "keeping innovating across platforms."
• Capacity & Supply: Leveraging a "vertically integrated national tissue supply network" and "best-in-class manufacturing process" to support growth.
• Commercial Scale: Accessing Sonara's network of "several hundred third-party agents" to expand commercial reach into new addressable markets.
• Financing: Strong balance sheet ($121M cash, no debt as of Q3) and committed financing secured to facilitate the Sonara transaction.

Risks and Headwinds to Outlook:

• Regulatory Risk: FTC approval for the Sonara acquisition remains the primary external hurdle; deal completion is not guaranteed until this is resolved.
• Reimbursement Volatility: The wound care market remains subject to "clumsy" Medicare reforms, causing revenue contraction and non-linear recovery dynamics.
• Litigation: While a $25 million IP infringement settlement was recently announced, the existence of IP disputes indicates ongoing litigation risks in the sector.
• Market Adoption: Success of the surgical expansion depends on the ability to continue generating "compelling beneficial health outcomes" and cost-avoidance data to persuade surgeons and hospital value analysis committees.

Management Tone on the Future:

• Confidence: Highly optimistic ("bullish about our future," "position of strength"), citing a transition from a struggling wound-centric model to a robust surgical platform.
• Hedges: Management qualifies the wound recovery as "sluggish" and the surgical growth as dependent on evidence generation and FDA approvals.
• Change vs. Prior: Management explicitly states the company has "changed" and "right-sized" its infrastructure, signaling a departure from previous struggles toward a "strong balance sheet" and "positive free cash flow."
• Execution Focus: Emphasis on the experienced leadership team's track record of scaling and integrating other medtech businesses as a confidence factor for successful execution.

Miscellaneous:

• Financial Metrics: Q3 2026 results showed net sales of $62 million (2/3 from surgical), a 9% dollar growth in surgical revenue, 80% gross margin, $121 million in cash, and no debt.
• Settlements: $25 million structured settlement reached with a wound care competitor regarding IP infringement.
• Clinical Evidence: Published data indicates amniofix grafts reduce anastomotic leak rates by roughly half and 30-day hospital readmissions by an "almost equivalent" amount in GI surgery.